Early glucagon-like peptide-1 receptor agonist use after myocardial infarction in patients with type 2 diabetes.
Ahmad. Omar O; Ibrahim. Ramzi R; Pham. Hoang Nhat HN; Abdelnabi. Mahmoud M; Elbenawi. Hossam H; Salih. Mohammed M; Farina. Juan J; Bhakta. Mayurkumar D MD; Sell-Dottin. Kristen A KA; Yang. Eric H EH; Sweeney. John P JP; Fortuin. F David FD; Simper. David D; Al-Kindi. Sadeer S; Lee. Kwan K; Nasir. Khurram K; Ayoub. Chadi C; Arsanjani. Reza R
Key Findings
- GLP‑1RA use within 14 days post‑MI did not lower recurrent coronary events (3.7% vs 3.8%).
- All‑cause mortality was reduced by about 52% (HR 0.48).
- Significant reductions in heart‑failure hospitalizations (HR 0.58), acute kidney injury (HR 0.69), cardiac arrest (HR 0.55), and any‑cause hospitalizations (HR 0.67).
Practical Outcomes
- For biohackers and self‑experimenters, the data suggest that adding semaglutide soon after a heart attack could be a powerful secondary‑prevention tool to boost survival and lower complications, even if it doesn’t stop another heart attack. Consider integrating a low‑starting dose (e.g., 0.25 mg weekly) and titrating up as tolerated, monitoring kidney function and heart‑failure signs. This protocol may be especially valuable for those already using GLP‑1RAs for metabolic health.
Summary
Starting a GLP‑1 receptor agonist like semaglutide (or tirzepatide) within two weeks after a heart attack in people with type‑2 diabetes didn’t cut the chance of another heart‑attack, but it cut the risk of dying, heart‑failure trips to the hospital, kidney injury, cardiac arrest, and overall hospital stays by roughly 30‑50% over about a year.
Abstract
Acute myocardial infarction (AMI) is among the leading causes of mortality in patients with type 2 diabetes (T2DM). This study evaluated whether initiation of glucagon-like peptide-1 receptor agonists (GLP1RAs) post-AMI improves cardiovascular outcomes in this population. This retrospective cohort study used the TriNetX Research Network to identify adult patients with T2DM who experienced an AMI between January 1, 2017, and December 31, 2023. Patients were included if they initiated tirzepatide or semaglutide within 14 days post-AMI. Propensity score matching (PSM) was performed to balance baseline characteristics. The primary outcome was recurrent coronary events, and secondary outcomes included all-cause mortality and hospitalizations, heart failure (HF) hospitalizations, acute kidney injury (AKI), and cardiac arrest. Hazard ratios (HR) were estimated using Cox proportional hazard models. 5338 patients were included in each cohort. Mean follow-up was 327.7 days (GLP1RA group) vs. 307.9 days (non-GLP1RA group). GLP1RA use did not significantly reduce recurrent coronary events (3.7 % vs 3.8 %; HR 0.913, 95 % CI 0.750-1.111). GLP1RA use was associated with significantly lower all-cause mortality (HR 0.484, 95 % CI 0.413-0.567), HF hospitalizations (HR 0.578, 95 % CI 0.531-0.630), AKI (HR 0.688, 95 % CI 0.610-0.732), cardiac arrest (HR 0.549, 95 % CI 0.418-0.722), and all-cause hospitalizations (HR 0.673, 95 % CI 0.636-0.713). GLP1RA initiation in patients with T2DM post-AMI was not associated with a reduction in recurrent coronary events, but was linked to improvements in other cardiovascular outcomes, suggesting a potential role for GLP1RAs as part of a secondary prevention strategy.
Study Information
pubmed
2025
2025-11-24T00:00:00.000Z
10.1016/j.ijcard.2025.134042
25